Median Technologies’ Global iCRO Team to participate in the 2023 ESMO Congress, Oct 20 – 24, 2023, Madrid, Spain
2023年10月16日 - 3:00PM
ビジネスワイヤ(英語)
- The iCRO team will be available at Booth #552, Exhibition Hall
5 during the entire industry exhibition duration.
- Members of the Median Technologies’ team across the globe,
including China, United States, and Europe, will be in
attendance.
- Median’s iCRO business provides best-in-class central imaging
services for oncology clinical trials.
Regulatory News:
Median Technologies (ALMDT:PA) announced today that the Company
will be participating in the prestigious 2023 European Society for
Medical Oncology (ESMO) Congress, set to take place in Madrid,
Spain (venue: IFEMA).
The event, scheduled from October 20th to 24th, promises to be a
remarkable platform for the exchange of groundbreaking insights and
cutting-edge developments in the field of oncology.
“As a testament to the commitment of advancing cancer care
worldwide, we will be participating with the goal of sharing our
expertise in clinical trial imaging as well as advanced, AI-powered
insights,” said Nicolas Dano, Chief Operating Officer, iCRO, of
Median Technologies. “We are thrilled to be bringing together for
the first time our expert teams spanning across the Europe, United
States, and China, and invite all attendees to visit booth #552 to
engage with our experts and experience firsthand the impact of our
pioneering solutions.”
More about the ESMO congress:
https://www.esmo.org/meeting-calendar/esmo-congress-2023
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and iBiopsy®, our
AI/ML tech-based suite of software as medical devices (SaMD), help
biopharmaceutical companies and clinicians to bring new treatments
and diagnose patients earlier and more accurately. This is how we
are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231015357688/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
過去 株価チャート
から 4 2024 まで 5 2024
Median Technologies (EU:ALMDT)
過去 株価チャート
から 5 2023 まで 5 2024